- Home
- PHUN vs LTRN Comparison
PHUN vs LTRN Comparison
Compare PHUN & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | LTRN |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 31.5M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PHUN | LTRN |
|---|---|---|
| Price | $1.72 | $2.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.25 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 91.8K | 48.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $95.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $2.34 |
| 52 Week High | $3.88 | $5.74 |
Technical Indicators
Market Signals| Indicator | PHUN | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 35.69 |
| Support Level | $1.60 | N/A |
| Resistance Level | $2.04 | $3.65 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 52.05 | 13.33 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.